Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...

Core Viewpoint - A securities class action lawsuit has been filed against Centene Corporation for allegedly misleading investors about its revenue outlook and growth projections during the specified class period [1][2]. Group 1: Allegations and Company Performance - The lawsuit claims that Centene misrepresented its revenue outlook and growth potential, while promoting favorable enrollment rates and low morbidity, which did not align with actual performance [2]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that its market growth across 22 states was lower than expected, leading to a revised guidance of approximately $1.8 billion and an adjusted diluted EPS of $2.75 [3]. - Following the announcement of the revised guidance, Centene's stock price plummeted by over 40% [3]. Group 2: Investor Actions - Investors who acquired Centene shares during the class period are encouraged to contact the law firm Gainey McKenna & Egleston before the lead plaintiff motion deadline on September 8, 2025 [4].

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Centene To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Centene between December 12, 2024 and June 30, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Faruqi ...

Core Viewpoint - The Centene class action lawsuit alleges that the company and its executives misled investors regarding the company's revenue outlook and growth potential, leading to significant financial losses for shareholders [4][5]. Company Overview - Centene Corporation is a healthcare enterprise that provides integrated services to government-sponsored and commercial healthcare programs, focusing on underinsured and uninsured individuals [3]. Allegations of the Lawsuit - The lawsuit claims that Centene created a false impression of reliable revenue projections and growth while overstating enrollment rates and underreporting morbidity [4]. - On July 1, 2025, Centene withdrew its 2025 guidance, revealing that market growth across 22 states was lower than expected, which led to a reduction in its guidance to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [5]. - Following this announcement, Centene's stock price fell by more than 40% [5]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Centene securities during the class period to seek appointment as lead plaintiff in the lawsuit [6]. - The lead plaintiff represents the interests of all class members and can select a law firm to litigate the case [6]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm specializing in securities fraud and shareholder litigation, having secured over $2.5 billion for investors in 2024 alone [7]. - The firm has been ranked 1 in securing monetary relief for investors in securities class action cases for four out of the last five years [7].

NEW YORK, July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/centene-corporation-lawsuit-submi ...

Core Viewpoint - A class action lawsuit has been filed against Centene Corporation for alleged violations of federal securities laws, claiming that the company made materially false and misleading statements regarding its business and operations [1][2]. Group 1: Class Definition - The lawsuit seeks damages on behalf of all individuals and entities that purchased Centene securities between December 12, 2024, and June 30, 2025, inclusive [2]. Group 2: Case Details - The complaint alleges that Centene made false and misleading statements while concealing adverse facts about its enrollment and morbidity rates [3]. - It is claimed that Centene's internal analysis indicated that its 2025 Health Insurance Marketplace growth across 22 states, which represents 72% of its marketplace membership, was significantly below expectations [3]. - As a result of these issues, Centene withdrew its 2025 guidance, reducing projected earnings to approximately $1.8 billion or an adjusted diluted EPS of $2.75 [3]. - Following these disclosures, Centene's stock price fell dramatically by 40.4%, from $56.65 per share on July 1, 2025, to $33.78 per share on July 2, 2025 [3]. Group 3: Next Steps - Investors who suffered losses in Centene have until September 8, 2025, to request to be appointed as lead plaintiff in the class action lawsuit [4].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, following significant discrepancies between the company's financial guidance and actual market conditions [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of New York, titled Lunstrum v. Centene Corporation, et al., No. 25-cv-05659, with investors having until September 8, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Centene securities [2]. Group 2: Company Background - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Group 3: Financial Guidance and Market Conditions - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company subsequently increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions revealed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Group 4: Stock Performance - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report indicated that market growth in 22 of the 29 states was lower than expected, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - A shareholder has filed a securities class action lawsuit against Centene Corporation for alleged misrepresentations regarding the company's enrollment and morbidity rates during a specified period [1][2]. Group 1: Lawsuit Details - The lawsuit is on behalf of investors who purchased or acquired Centene's securities between December 12, 2024, and June 30, 2025 [1]. - Defendants are accused of making misrepresentations about the state of Centene's enrollment and morbidity rates [2]. Group 2: Lead Plaintiff Information - Interested parties wishing to serve as lead plaintiff must file papers by September 8, 2025 [3]. - Serving as lead plaintiff is not a requirement for sharing in any potential recovery, and shareholders can remain absent class members if they choose not to take action [3]. Group 3: Law Firm Background - Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has represented large public and private pension funds [4]. - The firm has been recognized multiple times for its success in litigating class actions, being named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for sixteen consecutive years [4].

Core Viewpoint - Centene Corporation's shares experienced a significant decline after the company withdrew its guidance for 2025, indicating potential challenges ahead for the healthcare insurance provider [1] Group 1: Company Overview - Centene Corporation (NYSE: CNC) offers a range of healthcare insurance products, including Medicare and Medicaid [1] Group 2: Market Reaction - The withdrawal of guidance for 2025 has led to a plunge in Centene's stock price, reflecting investor concerns about the company's future performance [1]